Galmed Pharmaceuticals Ltd. (GLMD) Form 6-K — Jun 2, 2026
Galmed Pharmaceuticals and Tissue Dynamics announced preclinical results showing that a combination of Aramchol Meglumine and a selective PPAR-alpha agonist reduced cardiac fibrosis burden by approximately fourfold in human cardiac organoids. The study identified a previously unrecognized metabolic pathway driving cardiac fibrosis and heart failure, which was not detectable in conventional animal models. The collaboration leverages Tissue Dynamics’ human organoid models and AI platform to validate this mechanism, supporting Galmed’s strategy to expand Aramchol’s development beyond liver disease into cardiometabolic indications.
Key figures
- P value
- <0.001
- Fibrosis reduction
- 4-fold
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.